LP-IR (NMR Insulin Resistance): Which Tests to Order Alongside

At a glance

• What it is / A laboratory-derived score
• What it cannot do alone / Diagnose a condition or select treatment
• Useful context / Medical history, standard glucose tests, lipids, blood pressure, and medicines
• Best next step / Review the complete report with the clinician who ordered it

What an LP-IR score can add

An LP-IR result combines lipoprotein-particle measures into a score intended to reflect patterns associated with insulin resistance. A score is not a direct measurement of insulin action in an individual, and a high or low value does not establish a diagnosis. It should be interpreted with the laboratory method, reference range, medical history, and standard tests chosen for the clinical question.

For diabetes screening or diagnosis, clinicians use validated measures such as A1C or plasma glucose rather than an LP-IR score alone. The AACE diabetes algorithm emphasizes individualized assessment and treatment decisions. PubMed A laboratory pattern may prompt discussion, but it cannot determine that a person needs medication or predict an individual outcome.

Tests that may provide context

A clinician may consider fasting glucose, A1C, a standard lipid panel, blood pressure, weight history, medicines, sleep, and family history. Which tests matter depends on symptoms and risk factors. Repeating a broad panel on a fixed schedule or trying to change one score with supplements is not a validated care plan.

LDL cholesterol and triglycerides remain clinically important, but a single LP-IR result should not be used to override established cardiovascular-risk assessment. If a person has diabetes, kidney disease, pregnancy, unexplained weight change, or symptoms of high or low glucose, the appropriate evaluation may differ substantially.

Avoiding common misinterpretations

Do not treat LP-IR as proof that a person has insulin resistance, that a food caused a result, or that a particular treatment will work. Nutrition, activity, sleep, medicines, illness, and laboratory variation can all matter. A result that conflicts with A1C or glucose data is a reason for clinical review, not an invitation to self-adjust treatment.

The insulin-like growth-factor system has been discussed in obesity and diabetes research, but a review of that biology does not validate LP-IR as a diagnosis or a treatment target. PubMed

Questions that make the follow-up more useful

Ask which decision the LP-IR result is meant to inform and whether that decision is already addressed by standard testing. It is also useful to ask whether the sample was fasting, whether a recent illness or medication change could affect the surrounding results, and when a repeat test would actually change management. Those questions keep the discussion tied to a clinical purpose instead of treating a proprietary score as a stand-alone target.

When results disagree, the next step is not automatically more testing. A clinician may first confirm the report, review the laboratory's reference information, and compare the result with prior glucose, A1C, lipid, and blood-pressure measurements. The pattern over time and the person's overall risk profile are generally more informative than an isolated score.

Bottom line

LP-IR can be one piece of a clinician-directed risk discussion. Pair it with standard testing and clinical context, not a rigid protocol. Seek prompt care for symptoms such as confusion, fainting, severe vomiting, chest pain, or trouble breathing.

References

1. Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm: 2020 executive summary. Endocr Pract. 2020;26:107-139. PubMed
2. Lewitt MS, Dent MS, Hall K. The insulin-like growth factor system in obesity, insulin resistance and type 2 diabetes mellitus. J Clin Med. 2014;3(4):1561-1574. PubMed